Colorectal Cancer Clinical Trial
Official title:
A Phase I Open-Label, Single-Arm, Single-Centre Study to Establish Proof of Mechanism, Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of IMM-01 as Monotherapy in Checkpoint Inhibitor Naïve Patients With Advanced Solid Tumours
A study to assess the safety of IMM-01 in participants with advanced solid tumors
Status | Not yet recruiting |
Enrollment | 10 |
Est. completion date | July 2022 |
Est. primary completion date | July 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histological or cytological evidence of cancer (advanced solid tumours, excluding primary brain tumours) that is locally advanced and/or metastatic - Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale - Have an estimated life expectancy of greater than or equal to (=)12 weeks - Have adequate organ function - Renal: Estimated glomerular filtration rate (eGFR) =45 milliliters per minute (mL/min/1.73m2) - Have discontinued cytotoxic/cytostatic therapy, and cancer-related hormonal therapy at least 21 days or a minimum of 5 half-lives prior to study enrolment (6 weeks for mitomycin-C or nitrosoureas) and have discontinued radiotherapy at least 7 days prior to the first dose of study drug if radiation field did not encompass bone marrow. Or have recovered back to baseline or Grade 1 for any therapy related Adverse Events (AE) with the exception of alopecia or Grade 1 neuropathy - Have received at least 1 but no more than four prior systemic anti-cancer therapies for metastatic or locally advanced disease, including one immune-oncology agent - Have adequate venous access - Males and females with reproductive potential must agree to use medically approved contraceptives during the study and for 3 months following the last dose of study treatment - Females of child-bearing potential must have had a negative serum or urine pregnancy test result less than or equal to (=)28 days prior to the first dose of study treatment and a negative serum or urine pregnancy test result =1 day prior to the first dose - Tumour lesions that are considered evaluable by Response Evaluable Criteria in Solid Tumours (RECIST) Patients must be able to tolerate IV contrast for radiological evaluation - Have discontinued any prior immune-oncology agent at least 6 weeks prior to enrollment Additional Inclusion Criteria for Part A: - Amenable to undergo mandatory biopsies (baseline and on treatment) at dose levels that required them based on safety observations as well as requirements for demonstration of mechanism of action Additional Inclusion Criteria for Subset (approximately (~)50% per tumour type) of Part B: - Amenable to undergo mandatory biopsies (baseline and on treatment) - For Squamous Cell Carcinoma of the Head and Neck (SCCHN): - Must have failed at least one platinum-containing regimen for metastatic disease or experienced recurrent disease within 6 months of completing a platinum-containing regimen - For Squamous Cell Carcinoma (SCC) of the oesophagus: - Must have failed at least one platinum-containing regimen for metastatic disease or experienced recurrent disease within 6 months of completing a platinum-containing regimen - For metastatic Uveal Melanoma (UM): - May have failed up to four local liver therapies such as trans arterial chemoembolization (TACE) - May have failed up to two prior systemic therapies for metastatic disease - For Renal Cell Carcinoma (RCC): - May have failed up to four prior systemic therapies for metastatic or locally advanced disease including 1 immunotherapy agent - For Colorectal Cancer with mismatch-repair (MMR) deficiency - Must have failed at least one chemotherapy regimen for metastatic disease or experienced recurrent disease within 6 months - May have failed an anti-angiogenesis agent - May have failed an anti-epidermal growth factor receptor (EGFR) agent - May have failed one immunotherapy agent Exclusion Criteria: - Symptomatic central nervous system (CNS) metastasis. Patients with treated Central Nervous System (CNS) metastases are eligible, provided their disease is stable for minimum of 4 weeks, asymptomatic, and they are not currently receiving corticosteroids - Grade 2 or greater peripheral neuropathy - History of organ transplant (e.g., heart, lungs, liver, and kidney) - Females who are pregnant or nursing - Allogeneic bone marrow transplant - Prior Interleukin-2 (IL-2) treatment or known hypersensitivity to IL-2 - Patients with a history of active acquired immune deficiency syndrome (AIDS), who are known to be antigen positive Hepatitis B, or Hepatitis C - New York Heart Association (NYHA) Class 3 or 4 congestive heart failure, myocardial infarction (MI) or stroke within the past 6 months. Symptomatic bradycardia or other symptomatic conduction abnormities. Unstable angina. - Any medical condition which places the patient at unacceptable risk |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Modulate Therapeutics Ltd |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Part A: Maximum Tolerated Dose | Maximum tolerated dose as monotherapy | Baseline up to approximately 28 days (Cycle 1) | |
Primary | Part B: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) or Any Serious Adverse Events (SAEs) | Medical occurrences that emerge during treatment and were either absent pretreatment or have worsened relative to the pretreatment state | Baseline up to approximately 3 years | |
Secondary | Part A: Area under the concentration versus time curve during a dosing interval (AUC0-t) of losartan and its active metabolite (EXP3174) | Area under the concentration versus time curve during a dosing interval | Baseline up to approximately 28 days (Cycle 1) | |
Secondary | Part B: Area under the concentration versus time curve during a dosing interval (AUC0-t) of losartan and its active metabolite (EXP3174) | Area under the concentration versus time curve during a dosing interval | Baseline up to approximately 28 days (Cycle 1) | |
Secondary | Part A: Area under the concentration time curve from time zero to 24 hours post dose (AUC0-24) of losartan and its active metabolite (EXP3174) | Area under the concentration time curve from time zero to 24 hours | Baseline up to approximately 28 days (Cycle 1) | |
Secondary | Part B: Area under the concentration time curve from time zero to 24 hours post dose (AUC0-24) of losartan and its active metabolite (EXP3174) | Area under the concentration time curve from time zero to 24 hours | Baseline up to approximately 28 days (Cycle 1) | |
Secondary | Part A: Observed maximum plasma concentration (Cmax) of losartan and its active metabolite (EXP3174) | Following administration of IMM-01 | Baseline up to approximately 28 days (Cycle 1) | |
Secondary | Part B: Observed maximum plasma concentration (Cmax) of losartan and its active metabolite (EXP3174) | Observed maximum plasma concentration | Baseline up to approximately 28 days (Cycle 1) | |
Secondary | Part A: Time to Cmax (tmax) of losartan and its active metabolite (EXP3174) | Time to Cmax | Baseline up to approximately 28 days (Cycle 1) | |
Secondary | Part B: Time to Cmax (tmax) of losartan and its active metabolite (EXP3174) | Time to Cmax | Baseline up to approximately 28 days (Cycle 1) | |
Secondary | Part A: Apparent clearance of losartan and its active metabolite (EXP3174) | Apparent clearance | Baseline up to approximately 28 days (Cycle 1) | |
Secondary | Part B: Apparent clearance of losartan and its active metabolite (EXP3174) | Apparent clearance | Baseline up to approximately 28 days (Cycle 1) | |
Secondary | Part A: Volume of distribution of losartan and its active metabolite (EXP3174) | Volume of distribution | Baseline up to approximately 28 days (Cycle 1) | |
Secondary | Part B: Volume of distribution of losartan and its active metabolite (EXP3174) | Volume of distribution | Baseline up to approximately 28 days (Cycle 1) | |
Secondary | Part A: Elimination half-life (t1/2) of losartan and its active metabolite (EXP3174) | Elimination half-life | Baseline up to approximately 28 days (Cycle 1) | |
Secondary | Part B: Elimination half-life (t1/2) of losartan and its active metabolite (EXP3174) | Elimination half-life | Baseline up to approximately 28 days (Cycle 1) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |